Topical Diacerein Ointment for Epidermolysis Bullosa Simplex: A Review

Epidermolysis bullosa (EB) is a group of rare mucocutaneous fragility disorders often presenting in infancy and early childhood with painful blistering of the skin and mucous membranes. The severity of EB blister burden varies by disease subtype. Studies have shown that patients with generalized sev...

Full description

Saved in:
Bibliographic Details
Published in:Skin therapy letter 2019-05, Vol.24 (3), p.7-9
Main Authors: Limmer, Allison L, Nwannunu, Crystal E, Shah, Radhika, Coleman, Kendall, Patel, Ravi R, Mui, Uyen Ngoc, Tyring, Stephen K
Format: Article
Language:English
Subjects:
Administration, Cutaneous
Anthraquinones - administration & dosage
Anthraquinones - therapeutic use
Anti-Inflammatory Agents - administration & dosage
Anti-Inflammatory Agents - therapeutic use
Epidermolysis Bullosa Simplex - drug therapy
Humans
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epidermolysis bullosa (EB) is a group of rare mucocutaneous fragility disorders often presenting in infancy and early childhood with painful blistering of the skin and mucous membranes. The severity of EB blister burden varies by disease subtype. Studies have shown that patients with generalized severe epidermolysis bullosa simplex (EBS), a variant characterized by extreme fragility, develop blisters in the setting of overproduced, mutated K14 protein, a component of the intermediate filament integral in keratinocyte stability, and constitutive activation of interleukin (IL)-1 , a pro-inflammatory cytokine that promotes the hyperproliferation of keratinocytes. Diacerein, a rhein prodrug and anthraquinone, has been shown to reduce expression of K14 and inhibit IL-1 converting enzyme. In clinical trials, topical 1% diacerein was shown to be an effective and safe, non-invasive treatment for patients suffering from EBS. This review examines the clinical trials of topical diacerein and its role in EBS. Diacerein ointment was granted US FDA Rare Pediatric Disease designation in May 2018 and Fast Track development designation in August 2018.
ISSN:1201-5989